Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Publication year range
1.
Clin Infect Dis ; 77(Suppl 1): S62-S69, 2023 07 05.
Article in English | MEDLINE | ID: mdl-37406048

ABSTRACT

BACKGROUND: Our aim in this retrospective cohort study was to assess the impact on mortality of the empirical use of polymyxin as therapy for carbapenem-resistant gram-negative bacteria (CR-GNB) in septic patients. The study was performed at a tertiary academic hospital in Brazil, from January 2018 to January 2020, the pre-coronavirus disease 2019 period. METHODS: We included 203 patients with suspected sepsis. The first doses of antibiotics were prescribed from a "sepsis antibiotic kit", which contained a selection of drugs, including polymyxin, with no preapproval policy. We developed a logistic regression model to assess risk factors associated with 14-day crude mortality. Propensity score for polymyxin was used to control biases. RESULTS: Seventy (34%) of 203 patients had infections with at least 1 multidrug-resistant organism isolated from any clinical culture. Polymyxins in monotherapy or in combination therapy were prescribed to 140 of the 203 (69%) patients. The overall 14-day mortality rate was 30%. The 14-day crude mortality was associated with age (adjusted odds ratio [aOR], 1.03; 95% confidence interval [CI], 1.01-1.05; P = .01), SOFA (sepsis-related organ failure assessment) score value (aOR, 1.2; 95% CI, 1.09-1.32; P < .001), CR-GNB infection (aOR, 3.94; 95% CI, 1.53-10.14; P = .005), and time between suspected sepsis and antibiotic administration (aOR, 0.73; 95% CI, .65-.83; P < .001). The empirical use of polymyxins was not associated with decreased crude mortality (aOR, 0.71; 95% CI, .29-1.71; P = .44). CONCLUSIONS: Empirical use of polymyxin for septic patients in a setting with high CR-GNB prevalence was not associated with decreased crude mortality.


Subject(s)
COVID-19 , Gram-Negative Bacterial Infections , Sepsis , Humans , Polymyxins/therapeutic use , Carbapenems/pharmacology , Carbapenems/therapeutic use , Retrospective Studies , Anti-Bacterial Agents/therapeutic use , Gram-Negative Bacteria , Sepsis/drug therapy , Sepsis/epidemiology , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/epidemiology , Gram-Negative Bacterial Infections/microbiology
2.
J. pediatr. (Rio J.) ; J. pediatr. (Rio J.);74(2): 99-106, mar.-abr. 1998. ilus, tab
Article in Portuguese | LILACS | ID: lil-220066

ABSTRACT

Objetivos: Apresentar a experiência com os primeiros 12 transplantes hepáticos com doadores vivos realizados no Hospital Sírio-Libanês de Säo Paulo. Métodos: Foram utilizados como doadores 6 pais e 6 mäes com idade entre 30 e 48 anos. Todos os doadores form submetidos ao termo de consentimento esclarecido, à avaliaçäo clínica, laboratorial e radiológica, e à coleta prévia de sangue para autotransfusäo. A idade dos receptores variou de 7 meses a 10 anos e, o peso, de 6,3 a 34 kg. Seis receptores foram considerados de alto risco devido a complicaçöes da doença hepática avançada e foram submetidos ao transplante em caráter de urgência. Resultados: A mortalidade dos doadores foi nula, e o tempo médio de internaçäo foi de 10 dias. Foram observadas complicaçöes técnicas em 4 receptores, enquanto que, em 7, ocorreram um ou mais episódios de infecçäo bacteriana, viral ou fúngica. Um ou mais episódios de rejeiçäo, comprovados por biópsia, foram diagnosticados em 7 pacientes. A sobrevida dos receptores foi de 67 por cento, sendo 83 por cento nos casos eletivos e 50 por cento nos casos urgentes. O seguimento pós-operatório variou de 8 a 25 meses. Dos 8 sobreviventes, 7 apresentam excelente qualidade de vida e funçäo hepática normal...


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adult , Liver Transplantation , Living Donors , Postoperative Period
SELECTION OF CITATIONS
SEARCH DETAIL